Swedish start-up AI Medical Technology initiates clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing malignant melanoma
Stockholm, Sweden, May 2, 2022. On the first day of this year’s Skin Cancer Awareness Month, Swedish Artificial Technology start-up AI Medical Technologies announces the start of a clinical trial at 30 Swedish primary care facilities with Dermalyser, a diagnostic decision support system empowered with advanced artificial intelligence (AI). The study is a prospective, pivotal confirmatory multi-centre, non-interventional clinical investigation with the following aims:
1. Evaluate the clinical safety, performance and benefit of Dermalyser in patients with cutaneous lesions where malignant